As a matter of fact, dose escalation has improved distant metastasis-free survival (DMFS) and cancer-specific survival (CSS) [10–13]. However, the use of three-dimensional conformal radiation therapy (3D-CRT)

for dose escalation is limited by side effects [3–7, 14]; while intensity-modulated radiation therapy (IMRT) generally decreases treatment-related morbidity by producing steeper dose-gradients [13, 15–17]. At MSKCC [17, 18] the feasibility of dose escalation from 81 Gy to 86.4 Gy at 1.8 Gy/fraction in localized prostate ACY-1215 Cancer in association selleck chemicals llc with short course Androgen Deprivation Therapy (ADT) has been investigated, suggesting that ultra-high dose regimen is well tolerated and reporting an excellent biochemical control. However the role and the optimal duration of ADT with dose escalated radiation therapy still remains controversial. The aim of our paper is to report the outcome of a dose-escalation study with an ultra-high dose of 86 Gy at 2 Gy/fraction with IMRT technique in intermediate-risk prostate cancer patients, without the use of ADT, in terms of toxicity and biochemical control. Methods This is a single institution prospective click here phase II study approved by Regina Elena National Cancer Institute, Ethical Committee. Patients enrolled in the study belonged to the intermediate prognostic category according

to the National Comprehensive Cancer Network classification system (http://​www.​nccn.​com) which included patients with stage T2b-T2c tumors, and PSA >10 ng/ml but ≤ 20 ng/ml, and Gleason score 7. The clinical characteristics of patients and tumors

are shown in Table 1. Table 1 Clinical characteristics of patients and tumor staging Age (years)       Median (range) 72 (53–77) Follow-up (mos)       Median (range) 71 (32.8-93.6) Stage (N /%)       T1c 1 (2.5%) T2a 11 (28%) T2b 15 (38.5%) T2c 12 (31%) Gleason score       <=6 13 (33.3%) 7 (3 + 4) 20 (51.3%) 7 (4 + 3) 6 (15.4%) % Biopsy core       0-24% 12 (31%) 25-49% 16 (41%) 50-74% 10 (26%) 75-100% 1 (2%) iPSA       <10 37 (95%)   10–19.9 2 (5%) Inclusion criteria were: 1) age <80 years; 2) histological proof of prostate adenocarcinoma at intermediate risk; 3) risk of lymph node involvement < 15%, according to Roach formula, Gefitinib manufacturer or absence of adenopathy assessed by CT and/or MRI; 4) WHO performance status < 2; 5) no previous pelvic radiotherapy; 6) no previous prostate surgery; 7) no previous hormonal therapy; 8) no previous malignant tumors, with the exception of adequately treated cutaneous carcinomas; 9) declared availability to comply with the planned follow-up examinations; 10) written informed consent. All patients were free of ADT treatment. Written informed consent was signed by all patients. Patients underwent a CT simulation in the prone position by using a customized device for immobilization. A CT scan was performed at 5 mm intervals from L4/L5 to 5 cm below the ischial tuberosities.